AI Article Synopsis
- A study in South Korea assessed the frequency and severity of adverse events related to the Novavax COVID-19 vaccination for people aged 18 and older, beginning February 14, 2022.
- Data was gathered from two national systems: the COVID-19 vaccination management system (CVMS) and text-message surveys (TMS).
- Results showed lower adverse event reporting rates after booster doses compared to the first two doses, and fewer adverse events were reported in individuals aged 65 and older compared to those aged 18 to 64, indicating no major safety concerns.
Article Abstract
Background: In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 vaccination in Korea.
Methods: Adverse events based on two national vaccine safety data were analyzed; the COVID-19 vaccination management system (CVMS) and the text-message survey (TMS).
Results: CVMS identified that the reporting rate of adverse events per 100,000 doses were lower after booster doses (84.0) than after dose 1 (254.6) or dose 2 (272.9); and in 65-year-olds and over (83.4) than in 18- to 64-year-olds (168.1). The TMS found that local and systemic adverse events were lower in 65-year-olds and over than in 18- to 64-year-olds (p < 0.001).
Conclusions: Overall, we identified no major safety issues and fewer adverse events following the Novavax COVID-19 vaccination among 65-year-olds and over in Korea.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293897 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2023.06.077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!